PDE5 inhibitor efficacy is estrogen dependent in female heart disease

Journal of Clinical Investigation

Volumn 124, Issue 6, 2014, Pages 2464-2471

  Sasaki, Hideyuki ^a   Nagayama, Takahiro ^a   Blanton, Robert M ^b   Seo, Kinya ^a   Zhang, Manling ^a   Zhu, Guangshuo ^a   Lee, Dong I ^a   Bedja, Djahida ^a   Hsu, Steven ^a   Tsukamoto, Osamu ^c   Takashima, Seiji ^c   Kitakaze, Masafumi ^d   Mendelsohn, Michael E ^e   Karas, Richard H ^b   Kass, David A ^a   Takimoto, Eiki ^a,f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^e Mendelsohn Consulting Group LLC   (United States)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; ESTROGEN; GUANYLATE CYCLASE; NITRIC OXIDE SYNTHASE; PHOSPHOLAMBAN; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ESTROGEN THERAPY; FEMALE; GENE OVEREXPRESSION; HEART DISEASE; HEART FUNCTION; HEART PERFORMANCE; HEART PROTECTION; MUSCLE CELL; NONHUMAN; NUCLEOTIDE METABOLISM; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOTONIC AGENTS; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASE TYPE I; DISEASE MODELS, ANIMAL; ESTRADIOL; ESTROGENS; FEMALE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; GUANYLATE CYCLASE; HEART DISEASES; HEART FAILURE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; OVARIECTOMY; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RECEPTORS, ATRIAL NATRIURETIC FACTOR; SEX CHARACTERISTICS; SULFONES; TREATMENT OUTCOME;

EID: 84902185317     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70731     Document Type: Article

References (51)

1. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov. 2006;5(5):425-438.
2. Hsich EM, Pina IL. Heart failure in women: a need for prospective data. J Am Coll Cardiol. 2009;54(6):491-498.
3. Mosca L, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243-1262.
4. Reiner Z, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769-1818.
5. Takimoto E, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11(2):214-222.
6. Takimoto E, et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest. 2009;119(2):408-420.
7. Nagayama T, et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol. 2009;53(2):207-215.
8. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation. 2005;111(13):1601-1610.
9. Salloum FN, et al. Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide. Circulation. 2009;120(11 suppl):S31-S36.
10. Kim KH, et al. Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits of ventricular remodeling and exercise capacity. Circulation. 2012;125(11):1390-1401.
11. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebocontrolled study. Circ Heart Fail. 2011;4(1):8-17.
12. Billon-Gales A, et al. The transactivating function 1 of estrogen receptor α is dispensable for the vasculoprotective actions of 17β-estradiol. Proc Natl Acad Sci U S A. 2009;106(6):2053-2058.
13. Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci U S A. 2000;97(11):5930-5935.
14. Chambliss KL, et al. Non-nuclear estrogen receptor α signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest. 2010;120(7):2319-2330.
15. Bernelot Moens SJ, et al. Rapid estrogen receptor signaling is essential for the protective effects of estrogen against vascular injury. Circulation. 2012;126(16):1993-2004.
16. D'Angelo DD, et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A. 1997;94(15):8121-8126.
17. Dorn GW 2nd, Brown JH. Gq signaling in cardiac adaptation and maladaptation. Trends Cardiovasc Med. 1999;9(1-2):26-34.
18. Braz JC, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med. 2004;10(3):248-254.
19. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003;65:45-79.
20. Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev. 2006;86(1):1-23.
21. Blanton RM, et al. Protein Kinase G Iα inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. J Am Heart Assoc. 2012;1(5):e003731.
22. Michael SK, et al. High blood pressure arising from a defect in vascular function. Proc Natl Acad Sci U S A. 2008;105(18):6702-6707.
23. Takimoto E, et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest. 2005;115(5):1221-1231.
24. Knowles JW, et al. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest. 2001;107(8):975-984.
25. Saito T, Ciobotaru A, Bopassa JC, Toro L, Stefani E, Eghbali M. Estrogen contributes to gender differences in mouse ventricular repolarization. Circ Res. 2009;105(4):343-352.
26. Babiker FA, et al. 17beta-estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway. Circulation. 2004;109(2):269-276.
27. Andoh T, Chiueh CC, Chock PB. Cyclic GMP-dependent protein kinase regulates the expression of thioredoxin and thioredoxin peroxidase-1 during hormesis in response to oxidative stress-induced apoptosis. J Biol Chem. 2003;278(2):885-890.
28. Satoh M, et al. Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation. 2007;115(25):3197-3204.
29. Lu Q, Pallas DC, Surks HK, Baur WE, Mendelsohn ME, Karas RH. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc Natl Acad Sci U S A. 2004;101(49):17126-17131.
30. Sieveking DP, et al. A sex-specific role for androgens in angiogenesis. J Exp Med. 2010;207(2):345-352.
31. Yoshida S, et al. Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling. Circulation. 2013;128(1):60-71.
32. Zhou Y, Bourcy K, Kang YJ. Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signalling pathway. Cardiovasc Res. 2009;84(1):54-63.
33. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension. 2006;47(5):887-893.
34. Sano M, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007;446(7134):444-448.
35. McGill HC Jr, Anselmo VC, Buchanan JM, Sheridan PJ. The heart is a target organ for androgen. Science. 1980;207(4432):775-777.
36. Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation. 1998;98(3):256-261.
37. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA. Sildenafil inhibits β-adrenergic-stimulated cardiac contractility in humans. Circulation. 2005;112(17):2642-2649.
38. Takimoto E, et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res. 2005;96(1):100-109.
39. Takimoto E, et al. Compartmentalization of cardiac β-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation. 2007;115(16):2159-2167.
40. Shan X, Quaile MP, Monk JK, French B, Cappola TP, Margulies KB. Differential expression of PDE5 in failing and nonfailing human myocardium. Circ Heart Fail. 2012;5(1):79-86.
41. Vandenwijngaert S, et al. Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling. PLoS One. 2013;8(3):e58841.
42. Pokreisz P, et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation. 2009;119(3):408-416.
43. Zhang M, et al. Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J Am Coll Cardiol. 2010;56(24):2021-2030.
44. Redfield MM, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309(12):1268-1277.
45. Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol. 2006;47(9):1741-1753.
46. Donaldson C, et al. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation. Circ Res. 2009;104(2):265-275.
47. Patten RD, et al. 17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. J Card Fail. 2008;14(3):245-253.
48. Pedram A, Razandi M, Lubahn D, Liu J, Vannan M, Levin ER. Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-β to inhibit calcineurin. Endocrinology. 2008;149(7):3361-3369.
49. Koitabashi N, et al. Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J Clin Invest. 2011;121(6):2301-2312.
50. Moens AL, et al. Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the β3-adrenoreceptor. J Mol Cell Cardiol. 2009;47(5):576-585.
51. Watts VL, et al. Anti-hypertrophic and anti-oxidant effect of β3-adrenergic stimulation in myocytes requires differential neuronal NOS phosphorylation. J Mol Cell Cardiol. 2013;62:8-17.